Niagen Bioscience (NAGE) Company Report

Niagen Bioscience, Inc. acquired a comprehensive patent portfolio for nicotinamide riboside (NR) and its salt forms from Queen's University Belfast (QUB), establishing the company as the sole owner of this critical intellectual property.
The acquisition, effective December 16, 2025, includes foundational composition-of-matter patents, which are considered the strongest form of intellectual property protection.
As consideration, Niagen Bioscience will make a one-time payment of approximately $1,000,000 for accrued royalties through 2024, annual payments of $500,000 and £35,000 from 2026 to 2038, and additional one-time payments of $1,500,000 in 2035 and $2,000,000 in 2038.
This transaction terminates prior licensing and joint ownership agreements, releasing Niagen Bioscience from previous royalty and payment obligations.
Niagen Bioscience's intellectual property estate now totals more than 90 issued and pending patents worldwide, with over 50 focused solely on NR.

Dec 22, 2025, 1:32 PM

Niagen Bioscience Acquires Nicotinamide Riboside Patent Portfolio

NAGE

M&A

New Projects/Investments

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced on December 22, 2025, that it has acquired a comprehensive portfolio of existing patents covering nicotinamide riboside (NR) and its salt forms.
The patents were acquired from Queen’s University Belfast (QUB).
This acquisition further strengthens Niagen Bioscience’s long-standing leadership and ownership position in NAD+ precursor intellectual property.

Dec 22, 2025, 1:32 PM

Niagen Bioscience Acquires Patent Portfolio

NAGE

M&A

New Projects/Investments

Niagen Bioscience, Inc. acquired a comprehensive portfolio of existing patents covering nicotinamide riboside (NR) and its salt forms from Queen’s University Belfast (QUB).
This acquisition strengthens the company's leadership and ownership position in NAD+ precursor intellectual property.

Dec 22, 2025, 1:32 PM

Niagen Bioscience Announces Share Repurchase Program

NAGE

Share Buyback

Niagen Bioscience, Inc. (NAGE) announced on November 6, 2025, that its Board of Directors has approved a share repurchase program.
The program authorizes the company to repurchase up to $10 million of its outstanding common stock.
The repurchases can be made over the next 24 months, with the authorization expiring on October 31, 2027.
The timing, method, pricing, and actual amounts of any repurchases will be determined by management, and there is no obligation to repurchase any shares.

Nov 6, 2025, 2:05 PM

Niagen Bioscience, Inc. Reports Strong Q3 2025 Financial Results and Reaffirms Increased Full Year Outlook

NAGE

Earnings

Guidance Update

Product Launch

Niagen Bioscience, Inc. reported net sales of $34.0 million for the third quarter of 2025, marking a 33% increase year-over-year, with net income of $4.6 million and $0.06 earnings per share.
Adjusted EBITDA increased by 120% to $6.4 million for Q3 2025.
The company reaffirmed its full-year 2025 net sales outlook of 25% to 30% year-over-year growth, an increase from the previous guidance of 22% to 27%.
Recent operational highlights include the September 2025 launch of AboutNAD®, a digital platform for NAD+ research, and the October 2025 expansion of Niagen Plus™ IV and injectable therapies to over 1,000 clinics.

Nov 4, 2025, 9:01 PM

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook

NAGE

Guidance Update

Revenue Acceleration/Inflection

Niagen Bioscience, Inc. (NAGE) increased its full-year 2025 net sales outlook on October 6, 2025.
The revised outlook projects 25% to 30% year-over-year growth, an increase from the prior 22% to 27%.
The CEO noted that the FDA's latest reversal of previous rulings on the DSHEA drug preclusion rule relating to NMN could serve to increase awareness of the NAD+ precursor market.
Niagen Bioscience also stated that NMN products being sold on the market infringe upon an existing patent portfolio related to NMN crystallization.